CYP2C19 and major depressive disorder: In line with these findings, Serretti et al. [61] analyzed European patients with MDD treated with different antidepressant classes and observed that metabolic profiles associated with the CYP2C19*2 and *17 polymorphisms showed no significant association with treatment response or symptom remission.